Safety > Issues of Interest > Thimerosal
L, Ball R, Pratt RD. An assessment of thimerosal
in childhood vaccines. Pediatrics.
L, Hannulksela M, Kousa M, Lehmuskallio E.
Merthiolate hypersensitivity and vaccination.
Contact Dermatitis. 1980; 6:241-245.
RL, Lowe RS, Lanier BQ. Adverse reactions
to tetanus toxoid.
JAMA. 1982; 247:40-41.
statement concerning removal of thimerosal
from vaccines. The American Academy of Family
Physicians (AAFP), American Academy of Pediatrics
(AAP), Advisory Committee on Immunization
Practices (ACIP), and United States Public
Health Service (USPHS). Approved June 22,
Review on the toxicity of ethylmercury,
including its presence as a preservative
in biological and pharmaceutical products.
J. Appl. Toxicol. 2001; 21:1-5.
Methylmercury: A new look at the risks.
Public Health Reports. 1999;
ME, Cernichiari E, Lopreiato J, and Treanor
J. Mercury concentrations and metabolism
in infants receiving vaccines containing
thimerosal: a descriptive study. Lancet 360:1737-1741
Profile for Mercury (Update). Agency for
Toxic Substances and Disease Registry, Public
Health Service, US Department of Health and
Human Services. Atlanta, GA, 1999.
to main thimerosal page